LOGIN  |  REGISTER
Astria Therapeutics
Assertio

Singular Genomics Systems Announces Rescheduled Presentation Time at the UBS Genomics 2.0 and MedTech Innovations Summit

August 08, 2022 | Last Trade: US$20.01 0.00 0.00

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced its presentation time at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California has been rescheduled.

The new time for the fireside chat is 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time on the same day as previously scheduled, Thursday, August 11, 2022. Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation at investor.singulargenomics.com, in the Presentations & Events section.

About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine.

Investor Contact
Matt Clawson
949-370-8500
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Dan Budwick, 1AB
973-271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.


Assertio

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page